What is HC Wainwright's Forecast for CRDL Q1 Earnings?

Key Points

• HC Wainwright forecasts Q1 2026 EPS of ($0.06), reiterated a Buy rating with a $9.00 price target, and raised its FY2026 and FY2027 EPS estimates to ($0.27) and ($0.34) respectively (improving from earlier, more negative forecasts).
• Cardiol reported ($0.05) EPS for the most recent quarter, beating consensus by $0.04, but consensus full‑year EPS remains negative (~($0.33)) and the stock trades around $1.38 with a market cap near $154 million.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research report issued to clients and investors on Thursday, April 2nd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.34) EPS.

A number of other research analysts have also commented on CRDL. raised Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, February 3rd. Wall Street Zen raised Cardiol Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $8.00 price objective on shares of Cardiol Therapeutics in a report on Monday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cardiol Therapeutics currently has a consensus rating of "Hold" and an average price target of $8.50.

Cardiol Therapeutics Stock Down 1.1%

Shares of NASDAQ CRDL traded down $0.02 during mid-day trading on Tuesday, reaching $1.38. 522,206 shares of the company traded hands, compared to its average volume of 545,422. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.89 and a current ratio of 3.89. The stock has a market cap of $153.75 million, a PE ratio of -4.91 and a beta of 0.82. The company's fifty day moving average is $1.06 and its two-hundred day moving average is $1.05. Cardiol Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $1.59.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04.

Institutional Trading of Cardiol Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock valued at $36,000 after buying an additional 15,255 shares during the last quarter. Simplex Trading LLC grew its holdings in Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company's stock valued at $31,000 after buying an additional 15,842 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at approximately $31,000. Boyer Financial Services Inc. acquired a new stake in Cardiol Therapeutics in the 4th quarter valued at approximately $33,000. Finally, AdvisorShares Investments LLC grew its holdings in Cardiol Therapeutics by 7.3% in the 4th quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company's stock valued at $570,000 after buying an additional 40,589 shares during the last quarter. Institutional investors and hedge funds own 12.49% of the company's stock.

Trending Headlines about Cardiol Therapeutics

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a "Buy" rating and a $9.00 price target, and materially tightened/raised its EPS outlook — forecasting quarter-by-quarter EPS of ($0.06) and raising FY2026 to ($0.27) (from $0.41) and FY2027 to ($0.34) (from $0.51). Those upward revisions and the high price target are constructive for sentiment. MarketBeat: HC Wainwright Estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its "Buy" rating and set an $8.00 target, reiterating bullish analyst support and providing an additional near-term catalyst for buyers. Benzinga: Canaccord Reaffirmation
• Neutral Sentiment: Consensus full‑year EPS expectations remain negative (around ($0.33) per share), so despite analyst activity the company is still expected to report losses — this limits how strongly upgrades will translate to valuation changes. MarketBeat: Consensus Estimates
• Negative Sentiment: Brookline Capital Markets trimmed near-term and full‑year EPS forecasts (Q3 to ($0.08) from ($0.07), Q4 to ($0.09), and FY2026 to ($0.31) from ($0.29)), a downgrade that introduces downward pressure and highlights execution/forecast risk. MarketBeat: Brookline Estimate Cuts

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.